Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
grade C 18.52 -3.34% -0.64
BYSI closed down 3.34 percent on Wednesday, September 18, 2019, on 49 percent of normal volume.

Earnings due: Sep 18

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical BYSI trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
NR7 Range Contraction -3.34%
Wide Bands Range Expansion -3.34%
Down 3 Days in a Row Weakness -3.34%

Older signals for BYSI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Chemistry Biopharmaceutical Cancer Clinical Medicine Chemotherapy Cancer Treatments Organic Chemistry Antineoplastic Drugs Cancer Therapies Docetaxel Advanced Non Small Cell Lung Cancer Buparlisib Imidazoles Neutropenia
Is BYSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.86
52 Week Low 13.06
Average Volume 51,957
200-Day Moving Average 18.0126
50-Day Moving Average 17.5318
20-Day Moving Average 18.2075
10-Day Moving Average 19.734
Average True Range 1.3937
ADX 35.22
+DI 24.3947
-DI 12.7824
Chandelier Exit (Long, 3 ATRs ) 18.8189
Chandelier Exit (Short, 3 ATRs ) 19.5811
Upper Bollinger Band 21.7472
Lower Bollinger Band 14.6678
Percent B (%b) 0.54
BandWidth 38.881779
MACD Line 0.6656
MACD Signal Line 0.6101
MACD Histogram 0.0555
Fundamentals Value
Market Cap 423.07 Million
Num Shares 22.8 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -4.99
Price-to-Sales 0.00
Price-to-Book 16.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.23
Resistance 3 (R3) 20.41 20.03 19.95
Resistance 2 (R2) 20.03 19.59 19.94 19.85
Resistance 1 (R1) 19.27 19.32 19.08 19.09 19.75
Pivot Point 18.89 18.89 18.79 18.80 18.89
Support 1 (S1) 18.13 18.45 17.94 17.95 17.29
Support 2 (S2) 17.75 18.18 17.66 17.19
Support 3 (S3) 16.99 17.75 17.10
Support 4 (S4) 16.81